Shouji Matsushima
Assistant professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (12)
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
BACKGROUND: Mitral regurgitation (MR) is a frequent comorbidity in patients with hypertrophic cardiomyopathy (HCM), which includes distinct subtypes with various characteristics. However, data on the long-term prognostic impact of MR and its progression or regression over time remain limited, particularly across individual HCM subtypes. METHODS: Patients with HCM were retrospectively included from a Japanese multicenter registry and compared by MR severity (moderate or greater versus mild or less) within each subtype: hypertrophic obstructive cardiomyopathy (HOCM), end-stage HCM (ES-HCM), and other HCM (including nonobstructive, midventricular obstruction, and apical HCM). RESULTS: Among 3602 patients (HOCM: n=837; ES-HCM: n=275; other HCM: n=2490), the prevalence of moderate or greater MR was highest in HOCM (36.3%), followed by ES-HCM (21.5%) and other HCM (8.5%). During a median follow-up of 5.3 (interquartile range, 2.1–9.3) years, the cumulative 5-year incidence of all-cause death or heart failure hospitalization was not significantly different between the moderate or greater MR and mild or less MR groups in HOCM (14.6% versus 12.4%; P =0.35) or ES-HCM (60.7% versus 54.7%; P =0.84). After adjustment for clinical covariates, no significant association was observed in either subtype (HOCM: hazard ratio, 1.13 [95% CI, 0.79–1.60], P =0.51; ES-HCM: hazard ratio, 0.84 [95% CI, 0.55–1.28], P =0.42). In contrast, in other HCM, moderate or greater MR was significantly associated with the higher 5-year cumulative incidence of all-cause death or heart failure hospitalization (34.2% versus 13.9%, P <0.001), which remained significant after adjustment, with a significant interaction (hazard ratio, 1.45 [95% CI, 1.09–1.91], P =0.01; P interaction =0.02). MR severity improved over time in HOCM, showed no clear change in ES-HCM, and worsened in other HCM ( P <0.001, 0.46, and <0.001, respectively; P interaction <0.001). CONCLUSIONS: In patients with HCM, moderate or greater MR was not associated with worse outcomes in HOCM or ES-HCM, but had significant prognostic implications in other HCM subtypes, suggesting the need for HCM subtype-specific MR management.
Year:
2026
BACKGROUND: Sympathetic activation plays a role in heart failure (HF) development. Afferent renal nerve input may induce sympathoexcitation via the hypothalamic paraventricular nucleus (PVN), which projects to the rostral ventrolateral medulla, a center for sympathetic regulation. Central dendritic release of vasopressin from PVN neurons reportedly stimulates neighboring presympathetic neurons, causing sympathoexcitation. This study investigated whether afferent renal nerves contribute to hypertensive cardiac dysfunction and whether the afferent renal nerve-PVN axis mediates sympathoexcitation via central vasopressin using salt-loaded Dahl salt-sensitive rats, a model of hypertensive HF. METHODS: Salt loading began at 6 weeks of age, with selective afferent renal denervation and total renal denervation performed at 9 weeks in Dahl salt-sensitive rats. HF phenotypes were examined at 16 weeks, while sympathomodulation by afferent renal denervation was assessed at 12 weeks, the pre-HF phase. RESULTS: At 16 weeks, afferent renal denervation and total renal denervation similarly improved left ventricular systolic dysfunction, reduced myocardial fibrosis and related mRNA levels, and lowered plasma norepinephrine levels without reducing blood pressure in hypertensive rats. At 12 weeks, afferent renal denervation attenuated the increase in plasma norepinephrine and presympathetic neuron activity in the PVN and rostral ventrolateral medulla in hypertensive rats, while decreasing vasopressin-producing PVN neuron activity. In acute experiments, afferent renal nerve stimulation increased sympathetic outflow, but vasopressin V1a and V1b receptor blockade in the PVN suppressed this sympathoexcitation in hypertensive rats. CONCLUSIONS: Afferent renal nerve input activates the sympathetic nervous system before left ventricular systolic dysfunction and contributes to hypertensive HF, with PVN vasopressin driving this sympathoexcitation.
Year:
2026
Backgrounds Anemia is associated with poor prognosis in heart failure patients. Erythropoiesis‐stimulating agents have been used for the treatment of renal anemia, but they increase the risk of thrombotic events. Hypoxia‐inducible factor prolyl hydroxylase inhibitors (HIF‐PHIs) have emerged as a new treatment for renal anemia. HIF‐PHIs are expected to have pleiotropic effects beyond correcting anemia. Evidence regarding the effects of HIF‐PHIs in cardiorenal anemia syndrome has not been established. Methods and Results The present study is a single‐center, retrospective analysis of patients with heart failure and renal anemia who were treated with HIF‐PHIs or oral iron supplementation at Kyushu University Hospital ( n = 39 and n = 26). Both treatments significantly raised hemoglobin levels (HIF‐PHIs 9.1 [8.6–9.6] vs. 10.3 [9.5–11.8], p < 0.001; oral iron 10.1 [9.3–11.0] vs. 11.8 [10.6–13.2], p < 0.001). Log‐transformed BNP level (logBNP) decreased in the HIF‐PHI‐treated patients but not in those treated with oral iron despite the similar improvement in hemoglobin levels (HIF‐PHIs 2.74 [2.28–2.99] vs. 2.47 [2.16–2.66], p = 0.005; oral iron 2.38 [1.89–2.66] vs. 2.37 [1.90–2.50], p = 0.711). The levels of iron metabolism–related parameters after treatment were comparable between the two groups. Δ logBNP/ Δ Hb slope was significantly steeper in the HIF‐PHI group than the oral iron supplementation group (−0.100 vs. −0.047, p = 0.039), meaning that HIF‐PHIs further reduced BNP levels than anticipated by the increase of hemoglobin with conventional treatment. Conclusion HIF‐PHIs reduce BNP levels more than anticipated by the elevation of hemoglobin levels compared to oral iron supplementation. HIF‐PHIs may have therapeutic benefits against heart failure beyond the correction of anemia in the heart failure patients.
Year:
2025
Background Although a tool for sharing patient prognosis among all medical staff is desirable in heart failure (HF) cases, only a few simple HF prognostic scores are available. We previously presented the A 2 B score, a simple user‐friendly HF risk score, and validated it in a small single‐center cohort. In the present study, we validated it in a larger nationwide cohort. Methods and Results We examined the 2‐year mortality in relation to the A 2 B scores in 3483 patients from a Japanese nationwide cohort and attempted to stratify their prognoses according to the scores. The A 2 B score was determined by assigning points for age, anemia, and brain natriuretic peptide (BNP) level at discharge: age (<65 years, 0; 65–74 years, 1; ≥75 years, 2), anemia (hemoglobin ≥12 g/dL, 0; 10–11.9 g/dL, 1; <10 g/dL, 2), and BNP (<200 pg/mL, 0; 200–499 pg/mL, 1; ≥500 pg/mL, 2). Hemoglobin and BNP levels were applied to the data at discharge. The 2‐year survival rates for A 2 B scores 1, 2, 3, 4, 5, and 6 were 94.1%, 83.2%, 74.1%, 63.5%, 51.6%, and 41.5%, respectively; the mortality rate increased by ≈10% for each point increase (c‐index, 0.702). The A 2 B score was applicable in HF cases with reduced or preserved ejection fraction and remained useful when BNP was substituted with N‐terminal proBNP (c‐index, 0.749, 0.676, and 0.682, respectively). Conclusions The A 2 B score showed a good prognostic value for HF in a large population even when BNP was replaced with N‐terminal proBNP.
Year:
2024
Background The triglyceride/high-density lipoprotein cholesterol (TG/HDL-C) index, calculated as TG levels divided by HDL-C levels, is suggested as a predictor of cardiovascular disease (CVD). We investigated the association between the TG/HDL-C index and initial CVD events in high-risk patients with type 2 diabetes mellitus (T2DM). Methods We analyzed the association between the TG/HDL-C index and CVD events in T2DM patients with retinopathy and hyperlipidemia without known CVD enrolled in the EMPATHY study, which compared intensive and standard statin therapy (targeting LDL-C levels <70 mg/dL and ≥100 to <120 mg/dL, respectively). Results A total of 4665 patients were divided into high (TG/HDL-C ≥2.5, n =2013) and low (TG/HDL-C <2.5, n =2652) TG/HDL-C index groups. During a median follow-up of 36.8 months, 260 CVD events occurred. The high TG/HDL-C index group had higher CVD risk compared to the low TG/HDL-C index group (HR 1.89, 95% CI 1.45–2.47, p <0.001). This association was consistent across various subgroups. However, a trend toward interaction between the TG/HDL-C index and EMPATHY treatment allocation for CVD risk was observed ( p for interaction=0.062). Intensive statin treatment was associated with reduced CVD risk compared to standard treatment in the high TG/HDL-C index group but not in the low group. Conclusions A TG/HDL-C index ≥2.5 was associated with increased CVD risk in T2DM patients with retinopathy and hyperlipidemia without a history of CVD. The TG/HDL-C index may be a predictor of CVD and indicate patients who could benefit from intensive statin treatment.
Year:
2024
Year:
2023
Year:
2023
Collaborators (11)
Yasushi Sakata
Professor
Osaka University Graduate School of Medicine
Kaoru Dohi
Mie University Graduate School of Medicine
Takeshi Tohyama
Massachusetts Institute of Technology
Takahiro Okumura
Fujita Health University
Yudai Fujimoto
Juntendo University Hospital
Keisuke Kida
St. Marianna University School of Medicine
Shungo Hikoso
Nara Medical University
Issei Komuro
professor
University of Tokyo
Hiroki Shiomi
特定講師 / Program-Specific Senior Lecturer/Program-Specific Junior Associate Professor
Kyoto University
Toshitaka Okabe
Yokohama City University Medical Center
Shunsuke Katsuki
Kyushu University
Make your next move.
Prepare your application
Review drafts before you send them.